UNSPSC 51271629: Lidocaine hydrochloride

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V13007Z41A. European Medicines Agency schedules Lidocaine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02921MIG. Lidocaine hydrochloride generally arises in the molecular formula C14H22N2O.CLH.H2O. The term 'lidocaine hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation.

Most nations, for tariff and trade purposes, schedule lidocaine hydrochloride under HS 29242910 and SITC 51479. As of Q4 2014, LIDOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lidocaine hydrochloride bears US NLM identifiers UMLS ID C0546869 and NCI Concept Code C48000. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C)C.O.CL.

UNSPSC 51271629 Lidocaine hydrochloride is a Commodity code covering pharmaceutical active ingredients and finished-form products that state and local health systems, correctional facilities, public health agencies, and cooperative purchasing alliances procure for clinical and emergency-response use. The recent activity under this code centers on multi-source generic pharmaceutical procurement through cooperative purchasing vehicles, where state and local buyers source pharmaceutical ingredients and finished products—including injectable anesthetics such as lidocaine—through established wholesale distribution networks rather than direct manufacturer contracts. Issuing bodies are primarily state-level procurement offices administering multistate cooperative purchasing alliances on behalf of member jurisdictions; the Minnesota Department of Administration's Office of State Procurement, acting through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), represents the pattern of recent activity.

The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (Solicitation S1070000015802) posted January 20, 2026, with a due date of March 26, 2026, to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member states. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and comply with cGMP certification, Drug Supply Chain Security Act compliance, and FDA requirements. Pricing is weighted at 75 percent of the evaluation; competitive proposals use flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures, with awarded vendors paying a 3 percent administrative fee on all contract purchases. Contract awards become effective July 1, 2026, with a two-year term for new responders and optional extensions at MMCAP's discretion.